Xeris Biopharma Holdings annual stock-based compensation
2020
2021
2022
2023
2024
2025
Xeris Biopharma Holdings Stock-Based Compensation Growth & History (XERS)
Xeris Biopharma Holdings's stock-based compensation was $22.4M for fiscal 2025.
View full Xeris Biopharma Holdings company overviewXeris Biopharma Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $22.4M | $4.0M | +21.80% |
| 2024 | 2024-12-31 | $18.4M | $7.6M | +71.36% |
| 2023 | 2023-12-31 | $10.7M | −$1.4M | −11.88% |
| 2022 | 2022-12-31 | $12.2M | $779,000 | +6.84% |
| 2021 | 2021-12-31 | $11.4M | $3.1M | +37.57% |
| 2020 | 2020-12-31 | $8.3M | — | — |
Xeris Biopharma Holdings quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11.1M | $6.1M | +120.97% |
| Q1 2026 | 2026-03-31 | $4.1M | −$303,000 | −6.82% |
| Q4 2025 | 2025-12-31 | $5.3M | $1.7M | +46.65% |
| Q3 2025 | 2025-09-30 | $7.6M | $875,000 | +12.93% |
| Q2 2025 | 2025-06-30 | $5.0M | $775,000 | +18.31% |
| Q1 2025 | 2025-03-31 | $4.4M | $676,000 | +17.95% |
| Q4 2024 | 2024-12-31 | $3.6M | — | — |
| Q3 2024 | 2024-09-30 | $6.8M | $4.3M | +175.46% |
| Q2 2024 | 2024-06-30 | $4.2M | $1.3M | +44.57% |
| Q1 2024 | 2024-03-31 | $3.8M | — | — |
| Q3 2023 | 2023-09-30 | $2.5M | −$484,000 | −16.46% |
| Q2 2023 | 2023-06-30 | $2.9M | −$224,000 | −7.11% |
| Q4 2022 | 2022-12-31 | $2.8M | $23,000 | +0.84% |
| Q3 2022 | 2022-09-30 | $2.9M | −$724,000 | −19.75% |
| Q2 2022 | 2022-06-30 | $3.2M | $640,000 | +25.48% |
| Q1 2022 | 2022-03-31 | $3.3M | $840,000 | +34.13% |
| Q4 2021 | 2021-12-31 | $2.7M | — | — |
| Q3 2021 | 2021-09-30 | $3.7M | $1.6M | +78.43% |
| Q2 2021 | 2021-06-30 | $2.5M | — | — |
| Q1 2021 | 2021-03-31 | $2.5M | — | — |
| Q3 2020 | 2020-09-30 | $2.1M | — | — |
Xeris Biopharma Holdings stock-based compensation trends
Over the last five fiscal years, Xeris Biopharma Holdings's stock-based compensation increased from $8.3M to $22.4M, a change of $14.1M. The latest reported quarter, Q2 2026, shows $11.1M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xeris Biopharma Holdings source filings ↗